<?xml version="1.0"?>

<document>
	<title>Alpha-fetoprotein-like activity in sera from patients with malignant
   and non-malignant disease and healthy individuals.</title>

	<author>Norgaard-Pedersen-B.</author>
	<author>Axelsen-N-H.</author>

	<source>Clin-Chim-Acta. 1976 Sep 6. 71(2). P 343-7.</source>

	<abstract>A new method, radio-crossed immunoelectrophoresis, demonstrates alpha-
   fetoprotein (AFP) in sera with a sensitivity of 1 mug/1. By this
   method AFP with alpha mobility was not found in sera from healthy
   individuals, patients with chronic active hepatitis and cirrhosis,
   primary biliary cirrhosis, secondary liver cancer and cystic
   fibrosis. In some of the sera, AFP was elevated when measured by
   conventional radioimmunoassay method and the sera contained an AFP-
   like substance with gamma mobility when analyzed by radio-crossed
   immunoelectrophoresis. The nature of this gamma substance is still
   obscure and needs further investigation.</abstract>

	<majorsubject>ALPHA-FETOPROTEINS: me</majorsubject>
	<majorsubject>FETAL-PROTEINS: me</majorsubject>
	<majorsubject>LIVER-DISEASES: me</majorsubject>

	<minorsubject>COMPARATIVE-STUDY</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: me</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HEPATITIS: me</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>IMMUNOELECTROPHORESIS</minorsubject>
	<minorsubject>LIVER-CIRRHOSIS: me</minorsubject>
	<minorsubject>LIVER-NEOPLASMS: me</minorsubject>
	<minorsubject>PREGNANCY</minorsubject>

	<reference>001   ABELEV GI             ADV CANCER RES                  14   295 971</reference>
	<reference>002   NORGAARD-PEDERSEN B   ACTA PATH MICROBIOL SCAND       83   275 975</reference>
	<reference>003   RUOSLAHTI E           BR MED J                         2   527 974</reference>
	<reference>004   BELANGER L            PATHOL BIOL (PARIS)             21   449 973</reference>
	<reference>005   WALDMANN TA           LANCET                           2  1112 972</reference>
	<reference>006   CHANDRA RK            BR MED J                         1   714 975</reference>
	<reference>007   SEPPALA M             LANCET                           1   375 972</reference>
	<reference>008   RUOSLAHTI E           NATURE                         235   161 972</reference>
	<reference>009   RUOSLAHTI E           TRANSPLANT REV                  20    38 974</reference>
	<reference>010   NORGAARD-PEDERSEN B   CLIN CHIM ACTA                  48   345 973</reference>
	<reference>011   LEEK AE               COLLOQ INSERM ALPHA-FETOPRO          563 974</reference>
	<reference>012   DAMBRUYANT C          J IMMUNOL METH                   7   387 975</reference>
	<reference>013   MORGAN CR             DIABETES                        13   579 964</reference>
	<reference>014   PAGE LB               CLIN CHIM ACTA                  34    55 971</reference>
	<reference>015   FLORIN-CHRISTENSEN A  BR MED J                         2    94 973</reference>

	<citation>1   BROCK DJH             PROG MED GENET                   2     1 977</citation>
	<citation>2   NORGAARDPEDERSEN B    SCAND J CLIN LAB INVEST         37    46 977</citation>
	<citation>3   BJERRUM OJ            BIOCHIM BIOPHYS ACTA           472   135 977</citation>
	<citation>4   NORGAARDPEDERSEN B    CANCER                          41  2315 978</citation>
	<citation>5   SCHULTZ H             CANCER                          42  2182 978</citation>
	<citation>6   ADINOLFI M            ADV HUM GENET                    9   165 979</citation>
	<citation>7   RUOSLAHTI E           ADV CANCER RES                  29   275 979</citation>
	<citation>8   SOKOLENKO AA          BULL EXP BIOL MED               88  1093 979</citation>
	<citation>9   NORGAARDPEDERSEN B    CLIN GENET                      17   355 980</citation>

</document>
